A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology

Hepatology

Volumn 46, Issue 2, 2007, Pages 528-534

  Bellest, Laurent ^a   Eschwège, Valérie ^a   Poupon, Raoul ^b   Chazouillères, Olivier ^b   Robert, Annie ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; THROMBOPLASTIN;

ADULT; ARTICLE; BLOOD SAMPLING; CALIBRATION; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTHROMBIN TIME; STANDARDIZATION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; CALIBRATION; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE; MALE; MIDDLE AGED; PROTHROMBIN TIME; SEVERITY OF ILLNESS INDEX; THROMBOPLASTIN; VITAMIN K;

EID: 34548297386     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21680     Document Type: Article

References (34)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:457S-482S.
2. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendation for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2027-2049.
3. Ingram GI, Hills M. Reference method for the one-stage prothrombin-time in human blood. International committee for standardization in hematology. Thromb Haemost 1976;36:237-238.
4. Loeliger EA. The optimal therapeutic range in oral anticoagulation: history and proposal. Thromb Haemost 1979;42:1141-1152.
5. Poller L, TabernerDA. Dosage and control of oral anticoagulants: an international survey. Br J Haematol 1982;51:479-485.
6. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-1681.
7. World Health Organization Expert Committee on Biological Standardization. 33rd report: Technical Report Series, no. 687. Geneva, Switzerland: World Health Organization, 1983.
8. Poller L. International normalized ratios (INR): the first 20 years. J Thromb Haemost 2004;2:849-860.
9. Munoz SJ. Prothrombin time in fulminant hepatic failure. Gastroenterology 1991;100:1480.
10. Robert A, Chazouillères O. Prothrombin time in liver failure: time, ratio, activity percentage,or international ratio? HEPATOLOGY 1996;24:1392-1394.
11. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. HEPATOLOGY 2005;41:1179-1197.
12. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. HEPATOLOGY 2005; 42:282-292.
13. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. HEPATOLOGY 2006;43:1317-1325.
14. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001;33:464-470.
15. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. United Network for Organ Sharing Liver Disease Severity Score Committee: model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
16. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. HEPATOLOGY 2005;41:1-26.
17. Kovaks MJ, Wong A, MacKinnon K, Weir K, Keeny M, Boyle E, et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994;71:727-730.
18. Denson KWE, Reed SV, Haddon ME. Validity of the INR system for patients with liver impairment. Thromb Haemost 1995:713:162.
19. Kovacs MJ, Keeney M, MacKinnon K, Weir K, Boyle E. Rabbit brain-derived thromboplastins do not yield equivalent INRs for patients with liver impairment. Lab Hematol 1997;3:279-281.
20. Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004;10:995-1000.
21. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory rests. Clin Chem 2000;46:2027-2049.
22. World Health Organization Expert Committee on Biological Standardization. Guidelines for thromboplastins and plasma used to control anticoagulant therapy. WHO Technical Report Series 1999;889:64-93.
23. van den Besselaar AM, Barrowcliffe TW, Houbouyan-Reveillard LL, Jespersen J, Johnston M, Poller L, et al. Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost 2004;2:1946-1953.
24. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
25. Hemker HC, Veltkamp JJ, Hensen A, Loeliger EA. Nature of prothrombin biosynthesis: preprothrombinaemia in vitamin deficiency. Nature 1963;200:589-590.
26. Bertina RM, Westhoek-Kuipers ME, Alderkamp GH. The inhibitor of prothrombin conversion in plasma of patients on oral anticoagulant treatment. Thromb Haemost. 1981;45:237-241.
27. Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease. Lancet 2002;359:47-48.
28. Denson KW, Reed SV, Haddon ME, Woodhams B, Brucato C, Ruiz J. Comparative studies of rabbit and human recombinant tissue factor reagents. Thromb Res. 1999;94:255-261.
29. Grau E, Tenias JM, Olaso MA, Ferrando I, Juan MT, Pastor E, et al. Monitoring oral anticoagulant treatment from plasma stored for up to 48 hours and frozen plasma. Haematologica 1999;84:633-636.
30. Woodhams B, Girardot O, Blanco MJ, Colesse G, Gourmelin Y. Stability of coagulation proteins in frozen plasma. Blood Coagul Fibrinolysis 2001;12:229-236.
31. van den Besselaar AMHP, Houbouyan LL, Aillaud MF, Denson KWE, Johnston M, Kitchen S, et al. Influence of three types of automated coagulometers on the international sensitivity index (ISI) of rabbit, human, and recombinant human tissue factor preparations: a multicenter study. Thromb Haemost 1999;81:66-70.
32. Roberts JP, Dykstra DM, Goodrich NP, Rush SH, Merion RM, Port FK. Geographic differences in event rates by model for end-stage liver disease score. Am J Transplant. 2006;6:2470-2475.
33. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081-2089
34. Kountchev J, Bellmann R, Joannidis M. The prothrombin time point of the disseminated intravascular coagulation score. Crit Care Med 2005;33:1471.